{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:05:25Z","timestamp":1791439525906,"version":"4.3.3"},"reference-count":36,"publisher":"BMJ","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Belfast Health and Social Care Trust Charitable Funds","award":["no award\/grant number"],"award-info":[{"award-number":["no award\/grant number"]}]},{"name":"PARI GmbH","award":["no award\/grant number"],"award-info":[{"award-number":["no award\/grant number"]}]},{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["15\/100\/01"],"award-info":[{"award-number":["15\/100\/01"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2026,7,25]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>A drug response assessment (DRA) is recommended before starting patients on hypertonic saline (HTS) due to the risk of bronchoconstriction. As part of the CLEAR trial (a randomised, open-label trial of HTS and\/or carbocisteine versus usual care in bronchiectasis), we performed a post hoc analysis to explore the implementation and outcomes of DRAs. We aimed to remotely train\/assess research coordinators in performing DRAs and determine patient safety\/tolerability with HTS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Research coordinators were remotely trained\/deemed DRA competent. DRAs were conducted only in patients assigned HTS. Failure was classified as \u226515% forced expiratory volume in 1 s (FEV\n                      <jats:sub>1<\/jats:sub>\n                      ) drop or 10%\u201315%\u2009drop with respiratory symptoms.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      54 research coordinators (20 sites) were remotely trained\/deemed competent, and 52 conducted at least one DRA. 145 patients completed DRAs: 144 were correctly classified, one was misclassified as pass (found during quality checks). 12 were classified as fail in the first DRA: seven had \u226515% FEV\n                      <jats:sub>1<\/jats:sub>\n                      drop, two had 10%\u201315%\u2009FEV\n                      <jats:sub>1<\/jats:sub>\n                      drop with symptoms, one had severe coughing (clinical team did not recruit) and the reason was not documented for two. 11 repeated the DRA; nine passed and continued in the trial, two failed and were excluded. 142\/145 were classified as pass and entered the trial. Of 142 patients who continued in the trial, 46 later withdrew from HTS. 17 withdrawals were related to issues with HTS tolerance despite passing the first DRA.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>DRA failure rate was low and did not identify medium-term\/long-term tolerance to HTS, indicating that its utility as a screening tool for tolerability in this population is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"isrctn\" xlink:href=\"ISRCTN89040295\">ISRCTN89040295<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/thorax-2025-224572","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T17:20:29Z","timestamp":1785950429000},"page":"thorax-2025-224572","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Implementation and outcomes of drug response assessments for inhaled hypertonic saline in bronchiectasis: a post hoc analysis of the CLEAR trial"],"prefix":"10.1136","clinical-trial-number":[{"clinical-trial-number":"isrctn89040295","registry":"10.18810\/isrctn"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0647-2503","authenticated-orcid":false,"given":"Rebecca H","family":"McLeese","sequence":"first","affiliation":[{"name":"Wellcome Trust-Wolfson Northern Ireland Clinical Research Facility, Queen\u2019s University Belfast, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6471-1413","authenticated-orcid":false,"given":"Brenda","family":"O\u2019Neill","sequence":"additional","affiliation":[{"name":"Institute of Nursing and Health Research, Ulster University, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3283-1947","authenticated-orcid":false,"given":"Daniel F","family":"McAuley","sequence":"additional","affiliation":[{"name":"Wellcome-Wolfson Institute for Experimental Medicine, Queen\u2019s University Belfast, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2926-7257","authenticated-orcid":false,"given":"Mike","family":"Clarke","sequence":"additional","affiliation":[{"name":"Centre for Public Health, Queen\u2019s University Belfast, Belfast, UK"},{"name":"Northern Ireland Clinical Trials Unit, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Jackson","sequence":"additional","affiliation":[{"name":"Northern Ireland Clinical Trials Unit, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Campbell","sequence":"additional","affiliation":[{"name":"Northern Ireland Clinical Trials Unit, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Ferguson","sequence":"additional","affiliation":[{"name":"HSC Western Health and Social Care Trust, Londonderry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"McChrystal","sequence":"additional","affiliation":[{"name":"Wellcome Trust-Wolfson Northern Ireland Clinical Research Facility, Queen\u2019s University Belfast, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"De Soyza","sequence":"additional","affiliation":[{"name":"Population and Health Science Institute, Newcastle University and NIHR Biomedical Research Centre for Ageing, Freeman Hospital, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5514-7868","authenticated-orcid":false,"given":"James D","family":"Chalmers","sequence":"additional","affiliation":[{"name":"Scottish Centre for Respiratory Research, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Copeland","sequence":"additional","affiliation":[{"name":"PCD Family Support Group, Ciliopathy Alliance, Milton Keynes, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Stuart","family":"Elborn","sequence":"additional","affiliation":[{"name":"Wellcome-Wolfson Institute for Experimental Medicine, Queen\u2019s University Belfast, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy M","family":"Bradley","sequence":"additional","affiliation":[{"name":"Wellcome-Wolfson Institute for Experimental Medicine, Queen\u2019s University Belfast, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"2026080510202312000_thorax-2025-224572v1.1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2018-212463"},{"key":"2026080510202312000_thorax-2025-224572v1.2","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01126-2025","article-title":"European Respiratory Society clinical practice guideline for the management of adult bronchiectasis","volume":"66","author":"Chalmers","year":"2025","journal-title":"Eur Respir J"},{"key":"2026080510202312000_thorax-2025-224572v1.3","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.arbr.2017.07.014","article-title":"Spanish Guidelines on Treatment of Bronchiectasis in Adults","volume":"54","author":"Mart\u00ednez-Garc\u00eda","year":"2018","journal-title":"Archivos de Bronconeumolog\u00eda (English Edition)"},{"key":"2026080510202312000_thorax-2025-224572v1.4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5694\/mja14.00287","article-title":"Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand","volume":"202","author":"Chang","year":"2015","journal-title":"Med J Aust"},{"key":"2026080510202312000_thorax-2025-224572v1.5","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/resp.14479","article-title":"Thoracic Society of Australia and New Zealand (TSANZ) position statement on chronic suppurative lung disease and bronchiectasis in children, adolescents and adults in Australia and New Zealand","volume":"28","author":"Chang","year":"2023","journal-title":"Respirology"},{"key":"2026080510202312000_thorax-2025-224572v1.6","doi-asserted-by":"crossref","DOI":"10.1590\/1806-3713\/e20190122","article-title":"Brazilian consensus on non-cystic fibrosis bronchiectasis","volume":"45","author":"Pereira","year":"2019","journal-title":"J Bras Pneumol"},{"key":"2026080510202312000_thorax-2025-224572v1.7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4103\/atm.ATM_171_17","article-title":"The Saudi Thoracic Society guidelines for diagnosis and management of noncystic fibrosis bronchiectasis","volume":"12","author":"Al-Jahdali","year":"2017","journal-title":"Ann Thorac Med"},{"key":"2026080510202312000_thorax-2025-224572v1.8","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thx.2008.110726","article-title":"Guidelines for the physiotherapy management of the adult, medical, spontaneously breathing patient","volume":"64 Suppl 1","author":"Bott","year":"2009","journal-title":"Thorax"},{"key":"2026080510202312000_thorax-2025-224572v1.9","doi-asserted-by":"crossref","DOI":"10.1177\/1753466619866102","article-title":"Nebulized hypertonic saline in noncystic fibrosis bronchiectasis: a comprehensive review","volume":"13","author":"M\u00e1iz Carro","year":"2019","journal-title":"Ther Adv Respir Dis"},{"key":"2026080510202312000_thorax-2025-224572v1.10","doi-asserted-by":"crossref","unstructured":"Karliner J , Slotterback S , Boyd R , et al . Health Care\u2019s climate footprint how the health sector contributes to the global climate crisis and opportunities for action Health Care Without Harm Climate-smart. Eur J Public Health 2019. doi:10.1093\/eurpub\/ckaa165.843","DOI":"10.1093\/eurpub\/ckaa165.843"},{"key":"2026080510202312000_thorax-2025-224572v1.11","doi-asserted-by":"crossref","DOI":"10.1136\/thoraxjnl-2012-202678.240","article-title":"P179\u2005Nebulised 7% Hypertonic Saline as an Adjunct to Airway Clearance Can Be Commenced Safely in a Supervised Environment Without the Need For a Formal Bronchoconstriction Trial: Abstract P179 Table 1","volume":"67","author":"Mills","year":"2012","journal-title":"Thorax"},{"key":"2026080510202312000_thorax-2025-224572v1.12","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/ppul.25206","article-title":"Effectiveness of hypertonic saline nebulization in airway clearance in children with non-cystic fibrosis bronchiectasis: A randomized control trial","volume":"56","author":"Anuradha","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"2026080510202312000_thorax-2025-224572v1.13","first-page":"2653","article-title":"Inhalation of hypertonic saline: a promising therapy in bronchiectasis","volume":"127","author":"Koskela","year":"2011","journal-title":"Duodecim"},{"key":"2026080510202312000_thorax-2025-224572v1.14","doi-asserted-by":"crossref","unstructured":"Perez-Urria EA , Cisneros CV , Gir\u00f3n RM , et al . Nebulized saline treatment in patients with concomitant asthma and bronchiectasis. ERS International Congress 2021 abstracts; September 5, 2021 doi:10.1183\/13993003.congress-2021.PA2007","DOI":"10.1183\/13993003.congress-2021.PA2007"},{"key":"2026080510202312000_thorax-2025-224572v1.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2004.05.006"},{"key":"2026080510202312000_thorax-2025-224572v1.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2011.07.019"},{"key":"2026080510202312000_thorax-2025-224572v1.17","doi-asserted-by":"crossref","DOI":"10.1136\/thx.2010.150987.29","article-title":"P128 The challenges of hypertonic saline in non-CF bronchiectasis","volume":"65","author":"Small","year":"2010","journal-title":"Thorax"},{"key":"2026080510202312000_thorax-2025-224572v1.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2011.12.021"},{"key":"2026080510202312000_thorax-2025-224572v1.19","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1089\/jamp.2017.1443","article-title":"Impact of Hypertonic Saline Solutions on Sputum Expectoration and Their Safety Profile in Patients with Bronchiectasis: A Randomized Crossover Trial","volume":"31","author":"Herrero-Cortina","year":"2018","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"2026080510202312000_thorax-2025-224572v1.20","doi-asserted-by":"crossref","DOI":"10.1177\/1753466618787385","article-title":"Addition of hyaluronic acid improves tolerance to 7% hypertonic saline solution in bronchiectasis patients","volume":"12","author":"M\u00e1iz","year":"2018","journal-title":"Ther Adv Respir Dis"},{"key":"2026080510202312000_thorax-2025-224572v1.21","doi-asserted-by":"crossref","DOI":"10.1136\/thx.2010.151068.40","article-title":"P239 Audit of once daily nebulised hypertonic 6% saline (HTS) in adult non-CF bronchiectasis","volume":"65","author":"Pyne","year":"2010","journal-title":"Thorax"},{"key":"2026080510202312000_thorax-2025-224572v1.22","doi-asserted-by":"crossref","unstructured":"Housley GM , Sanghani N , Bush A . P84\u2005Longer term tolerability of nebulised hypertonic saline in children with respiratory disease. British Thoracic Society Winter Meeting 2017, QEII Centre Broad Sanctuary Westminster London SW1P 3EE, 6 to 8 December 2017, Programme and Abstracts; December 2017:LP\u2013A128. doi:10.1136\/thoraxjnl-2017-210983.226","DOI":"10.1136\/thoraxjnl-2017-210983.226"},{"key":"2026080510202312000_thorax-2025-224572v1.23","doi-asserted-by":"crossref","first-page":"146","DOI":"10.35787\/jimdc.v8i3.389","article-title":"Airway Clearance in Bronchiectasis: A Randomized Control Trial of N-Acetylcysteine with 3% hypertonic saline","volume":"8","author":"Shehzad","year":"2019","journal-title":"JIMDC"},{"key":"2026080510202312000_thorax-2025-224572v1.24","doi-asserted-by":"crossref","unstructured":"Bettany M , Pilsworth S , Barber D , et al . P4\u2005Nebulised medications in secondary care: rising to the challenge. British Thoracic Society Winter Meeting 2022, QEII Centre, Broad Sanctuary, Westminster, London SW1P 3EE, 23 to 25 November 2022, Programme and Abstracts; November 2022:LP\u2013A82. doi:10.1136\/thorax-2022-BTSabstracts.140","DOI":"10.1136\/thorax-2022-BTSabstracts.140"},{"key":"2026080510202312000_thorax-2025-224572v1.25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.medcli.2022.04.017","article-title":"Effectiveness of nebulized hypertonic saline in patients with bronchial hypersecretion","volume":"160","author":"Gonz\u00e1lez-Montaos","year":"2023","journal-title":"Med Clin (Barc)"},{"key":"2026080510202312000_thorax-2025-224572v1.26","doi-asserted-by":"crossref","unstructured":"Young R , Goode G , Jacques A , et al . An evaluation of physiotherapy-led inhalation testing in chronic respiratory disease at a tertiary centre. ACPRC Journal 2021;4\u201318. doi:10.56792\/CYYA3970","DOI":"10.56792\/CYYA3970"},{"key":"2026080510202312000_thorax-2025-224572v1.27","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.rmed.2018.06.008","article-title":"The utility of drug reaction assessment trials for inhaled therapies in patients with chronic lung diseases","volume":"140","author":"Dennis","year":"2018","journal-title":"Respir Med"},{"key":"2026080510202312000_thorax-2025-224572v1.28","doi-asserted-by":"crossref","DOI":"10.1136\/thoraxjnl-2011-201054b.106","article-title":"S106 A randomised double blind 13 week crossover trial of hypertonic saline (HTS) (6%) vs isotonic saline (ITS) (0.9%) in patients with bronchiectasis","volume":"66","author":"Bradley","year":"2011","journal-title":"Thorax"},{"key":"2026080510202312000_thorax-2025-224572v1.29","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14030907","article-title":"A Novel Medical Device for Airway Clearance","volume":"14","author":"Helper","year":"2025","journal-title":"J Clin Med"},{"key":"2026080510202312000_thorax-2025-224572v1.30","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJMoa2510095","article-title":"Hypertonic Saline or Carbocisteine in Bronchiectasis","volume":"393","author":"Bradley","year":"2025","journal-title":"N Engl J Med"},{"key":"2026080510202312000_thorax-2025-224572v1.31","unstructured":"Daniels T , Morrison L , Harnett N , et al . Standards of care and good practice for the physiotherapy management of cystic fibrosis. In: Association of Chartered Physiotherapists in Cystic Fibrosis. 3rd edn. 2017."},{"key":"2026080510202312000_thorax-2025-224572v1.32","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01451-2020","article-title":"Efficacy and safety of TOBI Podhaler in Pseudomonas aeruginosa-infected bronchiectasis patients: iBEST study","volume":"57","author":"Loebinger","year":"2021","journal-title":"Eur Respir J"},{"key":"2026080510202312000_thorax-2025-224572v1.33","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S2213-2600(24)00225-X","article-title":"Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months","volume":"12","author":"Haworth","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026080510202312000_thorax-2025-224572v1.34","doi-asserted-by":"publisher","DOI":"10.1111\/crj.13663"},{"key":"2026080510202312000_thorax-2025-224572v1.35","doi-asserted-by":"crossref","unstructured":"Nigro M , Polverino E , Crichton M , et al . Use of bronchodilators in bronchiectasis: data from EMBARC. ERS Congress 2024 abstracts; September 14, 2024:A2374. doi:10.1183\/13993003.congress-2024.PA2374","DOI":"10.1183\/13993003.congress-2024.PA2374"},{"key":"2026080510202312000_thorax-2025-224572v1.36","unstructured":"NHS . Delivering a \u2018net zero\u2019 national health service. 2020."}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2025-224572","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T17:20:33Z","timestamp":1785950433000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2025-224572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":36,"alternative-id":["10.1136\/thorax-2025-224572"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2025-224572","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]}}}